

Prospectus Exempt Offer

8.11% (8.11% p.a.) Barrier Reverse Convertible on Eli Lilly, Novo Nordisk (Quanto CHF)

Pricing Supplement

SSPA Designation: Barrier Reverse Convertible (1230)

The Pricing Supplement will not be filed with a Swiss reviewing body or any other competent authority according to article 45 of the Federal Act on Financial Services (FINSA). The Product may only be offered in accordance with the Selling Restrictions as set out below. In Switzerland, these financial instruments are considered structured products. They are not collective investment schemes within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA), and are therefore not subject to the regulations of the CISA or the supervision of the Swiss Financial Market Supervisory Authority FINMA. The investors bear the Issuer's credit risk.

PRODUCT DESCRIPTION

These products are characterised by one or several Coupons, several Barriers as well as by a – albeit only conditional – redemption at the Nominal Value. The redemption at the end of the term is determined on the basis of the performance and the closing prices of the respective Underlyings: A redemption at the Nominal Value takes place as long as no Barrier Event has occurred. If a Barrier Event has occurred but at Final Fixing all Underlyings are again higher than or equal to the respective Strike Prices, the Nominal Value is repaid. If, however, a Barrier Event has occurred and at Final Fixing at least one of the Underlyings closes lower than the corresponding Strike Price, the investor receives the delivery of the Underlying with the poorest performance or a cash compensation, corresponding to the closing price of this Underlying (for details see "Redemption/Delivery").

Product Conditions

ISIN / Swiss Security Number / Symbol

CH1548140941 / 154814094 / -

Issue Price 100.00% of the Nominal Value

Nominal Value CHF 1'000.00

Reference Currency CHF; issue, trading and redemption are in the Reference Currency

Initial Fixing 24 June 2026 (3:39 PM, local time Zurich)

Novo Nordisk A/S: 24 June 2026, intraday

Eli Lilly & Co.: 24 June 2026, intraday

Payment Date 01 July 2026

Last Trading Day 24 June 2027 (12:00 PM, local time Zurich)

Final Fixing 24 June 2027; Closing price on the Reference Exchange

Repayment Date 01 July 2027

Underlyings

Eli Lilly & Co. (further details on the Underlying see below)

Initial Reference Price USD 1'126.45

Strike Price USD 1'126.45 (100.00%*)

Barrier USD 563.23 (50.00%*)

Number of Underlyings ..
* in % of the Initial Reference Price

Novo Nordisk A/S (further details on the Underlying see below)

Initial Reference Price DKK 312.80

Strike Price DKK 312.80 (100.00%*)

Barrier DKK 156.40 (50.00%*)

Number of Underlyings ..

* in % of the Initial Reference Price

Number of Underlyings **	The Number of Underlyings will be calculated at Final Fixing according the following formula: $\text{Nominal Value} / \text{Strike} \times \text{Forex (Final Fixing)}$ Where: Forex(Final Fixing) is the exchange rate between the Underlying Currency and the Reference Currency at Final Fixing as observed on the relevant Fixing Page.
Fixing Page	Bloomberg BFIX, Bloomberg Index Services Limited, exchange rate between the Reference Currency and the currency of the Underlying at or around the time of determination of the Reference Price on the Final Fixing date.
Barrier Monitoring	24 June 2026 until 24 June 2027, continuous monitoring
Barrier Event	A Barrier Event shall be deemed to occur if during the Barrier Monitoring the price of at least one of the Underlyings is at or below the respective Barrier Level.
Coupon	8.1183% (8.1180% p.a.) 30/360 (number of days: 360)
Interest Component	0.0000% (Premium Component: 8.1183%)
Business Day Convention	Modified Following, Unadjusted
	If a Repayment Date or a Coupon Payment Date (each a "Relevant Payment Date") is not a Bank Business Day, the Relevant Payment Date shall be the next Bank Business Day, unless the Relevant Payment Date would therefore fall into the next calendar month, in this case the Relevant Payment Date shall be the immediately preceding Bank Business Day. The Coupon due on the Relevant Payment Date and, if applicable, the subsequent Coupon shall not be adjusted accordingly in the event of a postponement of a Relevant Payment Date.
Redemption / Delivery	- If no Barrier Event has occurred, at Repayment Date the Nominal Value is repaid - in addition to the Coupon. - If, however, a Barrier Event has occurred, repayment is as follows: 1. If at Final Fixing all closing prices of the Underlyings are higher than or equal to the corresponding Strike Price, the Nominal Value is repaid. In addition, the Coupon is paid out at Repayment Date. 2. If the Final Fixing of at least one Underlying is lower than the corresponding Strike Price, the investor receives a physical delivery of the indicated Number of the Underlying with the poorest performance; fractions are not accumulated and are paid out in cash, converted into the Reference Currency. In addition, the Coupon is paid out at Repayment Date.
Currency-hedged	Yes (Quanto CHF) In case of a physical delivery, the number of securities to be delivered will be defined based on the exchange rate between underlying currency and the reference currency at final fixing (for details see "Number of Underlyings" resp. "Redemption/Delivery").
Bondfloor upon issue	100% (Implied IRR: 0.00%)

Parties

Issuer	Opus (Public) Chartered Issuance S.A., Luxembourg, acting in respect of its Compartment 100 (no rating)
Lead Manager & Market Maker	Bank Vontobel AG, Zurich
Authorised Offeror	Bank Vontobel AG, Zurich
Paying and Calculation Agent	Bank Vontobel AG, Zurich
Custodian	Société Générale Luxembourg, Luxembourg
Trustee & Servicer to the Issuer	Chartered Investment Germany GmbH, Dusseldorf, Federal Republic of Germany
Reference Entity	EFG Bank AG, Zurich
Hedging Counterparty	Bank Vontobel AG, Zurich
Securities Agreement Counterparty	EFG Bank AG, Zurich
Supervision	Opus (Public) Chartered Issuance S.A. is authorized as a securitisation undertaking in Luxembourg and is subject to prudential supervision by the Commission de Surveillance du Secteur Financier (CSSF).

Costs and Charges

Distribution charges	The Issue Price includes distribution charges of 1.00%. Distribution charges may be paid as a discount on the Issue Price or as a one-time and/or periodic payment by the Issuer to one or more financial intermediaries.
----------------------	---

Further Information

Issue size	CHF 50'000, with the option to increase
Title	The products are issued in the form of uncertificated securities of the Issuer and registered as intermediated securities (<i>Bucheffekten</i>) pursuant to the Federal Intermediated Securities Act, FISA. No certificates, no title imprint.
Depository	SIX SIS AG
Clearing / Settlement	SIX SIS AG, Euroclear Brussels, Clearstream (Luxembourg)
Applicable Law / Jurisdiction	Swiss law (except for limited recourse and non-petition, which are subject to Luxembourg law) / Zurich 1, Switzerland
Publication of notices and adjustments	All notices to investors concerning the products and adjustments to the product terms (e.g. due to corporate

	actions) are published under the "Product history" of the respective product at https://markets.vontobel.com .
Early Termination	Only for fiscal or other extraordinary reasons, as well as in case of no outstanding positions (as specified in detail in the Private Placement Programme).
Secondary market trading	The Lead Manager intends, under normal market conditions, to provide a secondary market throughout the entire term, but do not assume any legal obligation to do so. Indicative daily prices of this product are available at https://markets.vontobel.com .
Price setting	Secondary market price quotations are "dirty", that is, accumulated interest is included.
Listing / Admission to trading	None
Minimum investment	CHF 1'000.00 Nominal Value
Minimum trading lot	CHF 1'000.00 Nominal Value

Tax treatment in Switzerland

Swiss Income Tax	This product qualifies as transparent with predominantly one-off interest payments (IUP). The return determined on the bond component of the product for the holding period is subject to direct federal taxes (modified taxation of the difference).
Swiss Withholding Tax	No Swiss withholding tax
Swiss Turnover Tax	Secondary market transactions are not subject to the Swiss turnover tax. If delivery of the underlying is stipulated, the swiss turnover tax may, however, be imposed.
General Information	Transactions and payments relating to this product may be subject to further (foreign) transaction taxes, duties and/or withholding taxes, in particular a withholding tax pursuant to the Section 871(m) of the US Internal Revenue Code. All payments from this product will occur with any applicable taxes and duties deducted. If delivery of the underlying is stipulated, foreign taxes and duties have to be assumed by the investors. The taxation mentioned is a non-binding and non-exhaustive summary of the applicable treatment of Swiss-domiciled private investors for tax purposes. The investor's specific circumstances, however, are not taken into account. We point out that Swiss and/or foreign tax law or the authoritative practice of Swiss and/or foreign tax authorities can change at any time or specify further tax or charge liabilities (possibly even with retrospective effect). Potential investors should have the tax effects of the purchase, holding, sale or repayment of this product examined by their own tax adviser - especially with respect to the effects of taxation under another jurisdiction.

Description of the Underlying

Eli Lilly & Co.	Name and type: Eli Lilly & Co., Registered Share Company and place of registration: Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285, United States Identification: ISIN US5324571083 / Bloomberg <LLY UN Equity> Reference Exchange: NYSE Futures exchange: Chicago Board Options Exchange; the Calculation Agent can determine another futures exchange at its discretion Performance: Available at www.nyse.com Transferability: According to the articles of incorporation of Eli Lilly Financial statements: Available at www.lilly.com
Novo Nordisk A/S	Name and type: Novo Nordisk A/S, Registered Share Company and place of registration: Novo Nordisk A/S, Novo Alle, 2880 Bagsvaerd, Denmark Identification: ISIN DK0062498333 / Bloomberg <NOVOB DC Equity> Reference Exchange: NASDAQ OMX Copenhagen Futures exchange: NASDAQ OMX Copenhagen; the Calculation Agent can determine another futures exchange at its discretion Performance: Available at www.bloomberg.com (Symbol: NOVOB:DC) Transferability: According to the articles of incorporation of Novo Nordisk Financial statements: Available at www.novonordisk.com

PROSPECTS OF PROFIT AND LOSSES

Any possible gain results from the fixed Coupon. Nevertheless, there is an upper limit to the gain, as the maximum payment is the Nominal Value plus the coupon. These products have only conditional repayment at the Nominal Value defined by the individual Barriers: If a Barrier Event has occurred, the right of a repayment at the Nominal Value ceases to apply immediately. Investors should be aware that this can happen during the relevant Barrier Monitoring (period of time or point(s) of time). Accordingly, the risks are considerable; given upwardly limited chances of gains, they correspond largely to the risks of a direct investment in the Underlying with the poorest performance. The lower the closing price of the Underlying with the poorest performance after falling below its Strike Price, the greater the losses sustained. In extreme cases, i.e. when the price of the Underlying is equal to zero (0), the maximum loss can lead to a loss of all the capital invested. Even if the performance of the Underlyings is positive and no Barrier Event has occurred, the price of the product during the term can be considerably below the Issue Price. Potential investors should bear in mind that price changes to the Underlyings, as well as other influencing factors, may have a negative effect on the value of products.

SIGNIFICANT RISKS FOR INVESTORS

Currency risks

If the Underlying or Underlyings is/are denominated in a currency other than the product's Reference Currency, investors should bear in mind that this may involve risks due to fluctuating exchange rates and that the risk of loss does not only depend on the performance of the Underlying(s) but also on any unfavourable performance of the other currency or currencies. This does not apply for currency-hedged products (quanto structure).

Market risks

The general market performance of Securities is dependent in particular on the development of the capital markets which, for their part, are influenced by the general global economic situation as well as by the economic and political framework conditions in the respective countries (so-called market risk). Changes to market prices such as interest rates, commodity prices or corresponding volatilities may have a negative effect on the valuation of the Underlying(s) or the product.

Disruption risks

There is also the risk of market disruptions (such as trading or stock market interruptions or discontinuation of trading) or other unforeseeable occurrences concerning the respective Underlyings and/or their stock exchanges or markets taking place during the term or upon maturity of the products. Such occurrences can have an effect on the time of redemption and/or on the value of the products.

In the event of trading restrictions, sanctions and similar occurrences, the Issuer is entitled, for the purpose of calculating the value of the product, to include at its own discretion the Underlying instruments at their most recently traded price, at a fair value to be established at its sole discretion or indeed as worthless, and/or additionally to suspend pricing in the product or liquidate the product prematurely.

Secondary market risks

Under normal market conditions, the Issuer or the Lead Manager intend to post bid- and ask-prices on a regular basis. However, neither the Issuer nor the Lead Manager is under any obligation with respect to investors to provide such bid- and ask-prices for specific order or securities volumes, and there is no guarantee of a specific liquidity or of a specific spread (i.e. the difference between bid- and ask-prices), for which reason investors cannot rely on being able to purchase or sell the products on a specific date or at a specific price.

Issuer risk

The value of the products may depend not only on the performance of the Underlying(s), but also on the creditworthiness of the Issuer, which may change during the term of the product. The investor is exposed to the risk of default of the Issuer.

The Issuer's sole business is the raising of money by issuing securities for the purposes of acquiring assets or risks relating to assets generally. Pursuant to the Luxembourg law of 22 March 2004 on Securitisation, as amended, claims against the Issuer by the holders of a security (the "Security Holders") will be limited to the net assets of the Compartment. The net assets of the Compartment will comprise (i) the Underlying Assets, and (ii) a cash account with an initial cash account amount of zero (the "Compartment Assets"). Other than as described in the foregoing, the Issuer will have no funds available to meet its obligations. If the Compartment Assets are not sufficient, there is a risk that the Issuer will temporarily or permanently not be able to fulfil its payment obligations when due and the Security Holders may suffer a loss. The entitlement of the investors is limited to the assets of the Compartment. In particular, the investors have no recourse/claim to any other assets of Opus (Public) Chartered Issuance S.A., including the assets of other compartments or the general assets of Opus (Public) Chartered Issuance S.A., which are not allocated to the Compartment.

During the term of the Securities, the rights of the Security Holders to be paid amounts due or for delivery of the Underlying under the Securities will be subordinated to (i) discharge of any liabilities towards creditors privileged by law, in particular existing tax liabilities of the Issuer (if any), to the extent that these are due and payable and (ii) discharge of any other liabilities of the Issuer in relation to the Compartment, in particular any administrative costs and the service fee. Any such claim rank priority to the claim of the Security Holders. Payment or delivery of such amounts will reduce the amounts that are available to the Issuer to make payments to the Security Holders.

The Company is structured to be an insolvency-remote vehicle, but it is under no circumstances insolvency-proof. If the Company fails for any reason to meet its obligations or liabilities, insolvency proceedings might be initiated. In any such circumstances, there is a risk that Security Holders may suffer a loss.

The Security Holders may be exposed to competing claims of other creditors of the Company, the claims of which have not arisen in connection with the creation, operation or liquidation of a Compartment if foreign courts, which have jurisdiction over assets of the Company allocated to a Compartment do not recognise the segregation of assets and limited recourse in that respect.

The Issuer is party to contracts with a number of third parties who have agreed to perform a number of services in relation to the Compartment Assets. In particular, the calculation agent, the paying agent and the depository agent have agreed to provide services with respect to the Compartment Assets. If any such third party fails to perform its obligations under any relevant agreement, the Security Holders may be adversely affected.

SELLING RESTRICTIONS

Any products purchased by any person for resale may not be offered in any jurisdiction in circumstances which would result in the Issuer being obliged to register any further documentation relating to this product in such jurisdiction.

The restrictions listed below must not be taken as definitive guidance as to whether this product can be sold in a jurisdiction. Additional restrictions on offering, selling or holding of this product may apply in other jurisdictions. Investors in this product should seek specific advice before on-selling this product.

Switzerland

The offer of Securities in Switzerland is exempt from the obligation to prepare and publish a prospectus in accordance with the Federal Act on Financial Services (FinSA). The product documentation has not been examined, approved or submitted to any reviewing body in the meaning of Article 52 FinSA.

Each offeror declares and guarantees that they have not submitted and will not submit a Public Offer of Securities that are the subject of the offer stipulated in this Private Placement Programme as set out in the Pricing Supplement, except for:

- (a) Offer to persons who have been defined as professional clients in accordance with the FINSA, or
- (b) Offer to fewer than 500 natural persons or legal entities (who are not professional clients in accordance with FINSA), or

- (c) Offer with a minimum denomination of CHF 100'000;
- (d) Offer under other circumstances that fall under Article 36 (1), Article 37 and/or Article 38 FINSA, or

where such an offer of Securities does not obligate the Issuer or Lead Manager to publish a prospectus in accordance with Article 35 FinSA or a supplement to a prospectus in accordance with Article 56 FinSA.

For the purposes of the above provision, the term "Public Offer of Securities" in relation to Securities in Switzerland means communication in any form and by any means in order to provide clients with sufficient information about the offer and the products offered to enable them to make a purchase decision or subscribe to the products.

United States, U.S. persons

The securities neither have been nor will be registered under the United States Securities Act of 1933, as amended (the "Securities Act") and the securities may neither be offered nor sold within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act).

Trading in the securities has not been and will not be approved by the United States Commodity Futures Trading Commission under the United States Commodity Exchange Act or by any other state securities commission nor has the Commodity Futures Trading Commission or any other state securities commission passed upon the accuracy or the adequacy of the Private Placement Programme. The Private Placement Programme may not be used in the United States and may not be delivered in the United States.

The securities will not be directly or indirectly offered, sold, traded or delivered within the United States or to or for the account or benefit of U.S. persons (as defined in Regulation S under the Securities Act).

Each offeror is required to agree that it will not offer or sell the securities as part of their distribution at any time within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the Securities Act).

The term "United States" as used herein means the United States of America, its territories or possessions, any state of the United States, the District of Columbia or any other enclave of the United States government, its agencies or instrumentalities.

European Economic Area (EEA)

In relation to each Member State of the European Economic Area any offeror of Securities represents and agrees that it has not made and will not make an offer of the Securities which are the subject of the offering contemplated by this Private Placement Programme as completed by the Pricing Supplement to the public in that Member State other than at any time:

- (a) to persons who are qualified investors as defined in the Prospectus Regulation;
- (b) to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), subject to obtaining the prior consent of the Lead Manager for any such offer; or
- (c) in any other circumstances falling within Articles 1(3), 1(4) and/or 3(2)(b) of the Prospectus Regulation,

provided that no such offer of Securities shall require the Issuer or Lead Manager to publish a prospectus pursuant to Article 3 of the Prospectus Regulation.

For the purposes of the provision above, the expression an "offer of securities to the public" in relation to any securities in any Member State means the communication in any form and by means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe for the securities, and the expression "Prospectus Regulation" means Regulation (EU) 2017/1129, and includes any relevant implementing measure in the relevant Member State.

United Kingdom

With respect to the United Kingdom, each person offering the securities must represent and agree that it has not made and will not make an offer of securities to the public in the United Kingdom that are the subject of this Base Prospectus, except that an offer of such securities in the United Kingdom may be made:

- (a) in relation to any products which have a maturity of less than one year, (i) it is a person whose ordinary activities involve it in acquiring, holding, managing or disposing of investments (as principal or agent) for the purposes of its business and (ii) it has not offered or sold and will not offer or sell any products other than to persons whose ordinary activities involve them in acquiring, holding, managing or disposing of investments (as principal or as agent) for the purposes of their businesses or who it is reasonable to expect will acquire, hold, manage or dispose of investments (as principal or agent) for the purposes of their businesses where the issue of the products would otherwise constitute a contravention of section 19 of the Financial Services and Markets Act 2000 ("FSMA") by the Issuer;
- (b) it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) received by it in connection with the issue or sale of any products in circumstances in which section 21(1) of the FSMA does not apply to the Issuer; and
- (c) in any other circumstances falling within Part 1 of Schedule 1 of the POATRs.

Further risk information and selling restrictions

Please also note the additional risk factors and selling restrictions set out in detail in the Private Placement Programme.

LEGAL NOTICES

Product documentation

This document ("Pricing Supplement") contains the final terms for the Product. This document has not been prepared in accordance with the requirements of article 35 ff. FinSA.

The Pricing Supplement, together with the "Opus (Public) Private Placement Programme for the issuance of Securities" in the currently valid version ("Private Placement Programme"), which are written in English (foreign language versions represent non-binding translations), represent the entire documentation for this product (the "Programme") and accordingly the Pricing Supplement should always be read in conjunction with the Private Placement Programme and any supplements thereto, if any. Definitions used in the Pricing Supplement but not defined herein have the meanings given to them in the Private Placement Programme.

In the event of any conflict between this Pricing Supplement and the Private Placement Programme, the provisions of the Pricing Supplement shall prevail. The Issuer is entitled at any time to correct typographical or arithmetic errors or other obvious errors in this Pricing Supplement and conditions and to make editorial changes as well as to change or add to contradicting or incomplete provisions without the consent of the investors. The Issuer has no obligation to issue the product. The Private Placement Programme can be obtained from Opus (Public) Chartered Issuance S.A., 28 Boulevard F.W. Raiffeisen, L-2411 Luxembourg, Grand Duchy of Luxembourg (telephone +352 27 86 03 72) and can also be accessed on the website <https://markets.vontobel.com/en-ch>. The Issuer expressly disclaims any liability for publications on other Internet platforms. Notifications in connection with this product will be rendered legally valid upon their publication as described in the Private Placement Programme. When replacing the Private Placement Programme with a successive version of the Private Placement Programme, the Pricing Supplement must be read together with the most recent valid successive version of the Private Placement Programme (in each case, a "Successive Private Placement Programme"), which either (i) replaced the Private Placement Programme, or (ii) if one or more Successive Private Placement Programmes to the Private Placement Programme have already been prepared, the most recent Successive Private Placement Programme and the term Programme must be interpreted accordingly. The Issuer consents to the use of the Private Placement Programme (including any subsequent Private Placement Programmes) together with the respective Pricing Supplement in connection with an offer of the products by a financial intermediary who is authorised to make such offers.

Further information

The list and information shown do not constitute a recommendation concerning the Underlying in question; they are for information purposes only and do not constitute either an offer or an invitation to submit an offer, or a recommendation to purchase Financial Products. Indicative information is provided without warranty. The information is not a substitute for the advice that is indispensable before entering into any derivative transaction. Only investors who fully understand the risks of the transaction to be concluded and who are commercially in a position to bear the losses which may thereby arise should enter into such transactions. Furthermore, we refer to the brochure "Risks Involved in Trading Financial Instruments" which is available upon request.

Zurich, 24 June 2026 / Deritrade-ID: 6055912084
Opus (Public) Chartered Issuance S.A., Luxembourg